NCT03915951 2026-03-24
An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer
Pfizer
Phase 2 Completed
Pfizer
Pierre Fabre Medicament
Intergroupe Francophone de Cancerologie Thoracique
Abramson Cancer Center at Penn Medicine
Pfizer